MetaCap

Polaryx Therapeutics Inc. (PLYX)

NASDAQ: PLYXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.33-0.18 (-11.92%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PLYX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$66.30M
EPS (TTM)
-$0.18
52-week range
1.30 – 48.91
Day range
1.30 – 1.56
Volume / Avg
49.40K / 36.42K
Beta
—

52-week range

$1.30$48.91

PLYX stock today

On Nov 20, PLYX ended the session at $1.33, shedding $0.18 (11.92%), versus the S&P 500's 3.70% decline. Shares are 97.3% below their 52-week high of $48.91, set on Feb 2, 2026 and 2.3% above the 52-week low of $1.30, near the bottom of the past year's range. Polaryx Therapeutics has posted a net loss over the last twelve months (EPS of -$0.18), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Polaryx Therapeutics

Company profile

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Alex Yang J.D., L.L.M.
Headquarters
Paramus, NJ
Employees
2

Financial highlights

Full financials

Polaryx Therapeutics reported a net loss of $9.0 million, compared with a loss of $30.4 million a year earlier. Diluted earnings per share came in at -$0.20.

Polaryx Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024
Revenue——
Growth——
Net income$-8.98M$-30.36M
EPS (diluted)$-0.20$-0.89

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$7.50+463.91%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $6.00High $10.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.07 vs $-0.05
Surprise
-40.00%

PLYX news

All PLYX news

Polaryx Therapeutics peers

Health Care sector
PLYX peer companies
CompanyPrice% ChgMarket capCompare
PMVPPMV Pharmaceuticals Inc.0.876-33.13%$66.17Mvs PLYX
GOSSGossamer Bio Inc.10.72-4.54%$65.57Mvs PLYX
MNOVMedicinova Inc1.31+3.15%$67.11Mvs PLYX
CINGCingulate Inc.4.51-14.26%$67.48Mvs PLYX
FBIOFortress Biotech Inc.1.90+7.34%$64.11Mvs PLYX
MAIAMAIA Biotechnology Inc.1.11-2.63%$68.54Mvs PLYX
COYACoya Therapeutics Inc.2.95-1.01%$69.20Mvs PLYX
ZYBTZhengye Biotechnology Holding Limited Class A1.48-2.63%$70.14Mvs PLYX

Indexes, lists and sector

Polaryx Therapeutics stock FAQ

What is Polaryx Therapeutics's stock price today?

PLYX last traded at $1.33 as of Nov 20, 4:00 PM EST, down 11.92% on the day. Prices are delayed at least 15 minutes.

Who is Polaryx Therapeutics's CEO?

Mr. Alex Yang J.D., L.L.M. is the chief executive officer of Polaryx Therapeutics Inc., which has about 2 employees.

What is the PLYX 52-week high?

The 52-week high for PLYX is $48.91 and the 52-week low is $1.30. The stock is currently 97.3% below its high.

Compare PLYX